ACTU
Actuate Therapeutics, Inc.
$1.52
+0.12 (+8.57%)
At close · Jul 7
Market Cap
$36.37M
Shares
23,925,852
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.52
Open$1.37
Day$1.37–1.54
52W$1.37–9.22
Avg vol 30d168K
Short int915K · 3.8% float · 4.4d
Short vol64%
DataAug 2024–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−66%
below
Price vs 50-day avg
−33%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
2%
near low
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−74%
trailing
YTD return
−75%
this year
Relative strength
−81%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
2 of 60 funds reported for Jun 30 · net +9.8K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.83% of float · ▼ -0.6% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
60 holders — near 1-yr high, broad support
Squeeze score
52
elevated · 0–100
Fundamentals
EPS growth
+67%
Y/Y
Balance sheet
$13.2M
net cash
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
15.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−66%
Bearish
Price vs 50-day avg
−33%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
2 of 60 funds reported for Jun 30 · net +9.8K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.83% of float · ▼ -0.6% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
60 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $2 · 2%
52-wk high $9
vs 200-day avg -66%
vs 50-day avg -33%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACTU
this stock
Actuate Therapeutics, Inc.
|
$36.37M | -75.2% | — | — | 3.8% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACTU | -3.8% | -19.2% | -73.6% | -0.7% | -75.2% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -4.7% | -20.5% | -81.1% | -0.8% | -84.8% |